Objective: A Korean herbal formulation, Ojayeonjonghwan, is used to treat late-onset hypogonadism (LOH) symptoms including erectile dysfunction (ED). A previous study demonstrated that a modified Ojayeonjonghwan (KH-204) could be developed as a therapeutic alternative medicine to improve ED. We examined the pharmacological effects of KH-204 in vitro and in an androgen-deprived rat model. Methods: The survival rate of TM3 Leydig cells treated with KH-204 was measured based on oxidative stress. Androgen-deprivation was induced by s.c. injection of leuprorelin. After daily intake of KH-204 for four weeks, the testes and epididymides from rats in all groups were removed, weighed and subjected to histological examination. In addition, testosterone level, oxidative stress, and apoptosis were measured. Results: The results showed that KH-204 protected TM3 cells from oxidative stress via activation of the ERK and Akt pathways. The level of testosterone and activation of spermatogenesis in androgen-deprived male rats were significantly enhanced, and germ cell apoptosis was reduced after treatment.
AB098. Can concomitant dutasteride reduce the effect of testosterone replacement therapy in men with late-onset hypogonadism? A 24-week, randomized, parallel study Objectives: 5ARIs have sexual side effects, including erectile dysfunction (ED), loss of libido and ejaculatory dysfunction due to their action mechanism which decreases serum DHT levels. We examined whether concomitant dutasteride reduced the efficacy of testosterone replacement therapy (TRT) in men with late-onset hypogonadism. Methods: This was a 24-week, randomized, parallel study of the clinical outcomes in men age >40 years with symptomatic benign prostatic hypertrophy [BPH; International Prostate Symptom Score (IPSS) th], prostate volume Prostate Symptom Score (IPSS) 300 ng/dL with aging male symptoms, who were taking stable doses of alpha-blockers 4 weeks before participation. Eligible patients received a combination of dutasteride 0.5 mg once daily and a transdermal gel containing 10 g testosterone (T) (DT group, n=30) or the transdermal gel alone (T group, n=30). The primary outcomes were the change in the aging male symptom (AMS) score, sexual desire (question 17, AMS score), and erectile function (International Index of Erectile Function-5). Secondary outcomes were the posttreatment IPSS, peak urinary flow rate, post-void residual urine volume (PVR), and prostate volume. Results: Both groups showed significant improvements from baseline in all primary outcome parameters. However, there were no significant differences in the changes in the AMS total score (DT −5.2 vs. T −5.0; P=0.55), sexual desire (DT −2.5 vs. T −2.3; P=0.23), and IIEF-5 score (DT −2.1 vs. T −1.9; P=0.13) between groups. The extent of IPSS improvement from baseline to 24 weeks was the same in
